Form 4: Nuvalent Chief Development Officer Executes Pre-Planned Stock Option Exercises and Sales

Nuvalent, Inc.'s Chief Development Officer, Darlene Noci, engaged in pre-planned transactions on May 29, 2025, exercising stock options and simultaneously selling an equivalent number of Class A Common Stock shares under a Rule 10b5-1 trading plan.

Summary

• Darlene Noci, Chief Development Officer of Nuvalent, Inc. (NUVL), reported transactions on May 29, 2025, involving the company's Class A Common Stock.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Noci on November 18, 2024.
• Ms. Noci acquired a total of 4,000 shares of Class A Common Stock through the exercise of stock options: 2,129 shares at an exercise price of $14.40 and 1,871 shares at an exercise price of $27.85.
• Concurrently, Ms. Noci disposed of a total of 4,000 shares of Class A Common Stock through sales: 3,437 shares at a weighted average price of $71.25 (ranging from $70.49 to $71.46) and 563 shares at a weighted average price of $71.67 (ranging from $71.62 to $71.76).
• Following these transactions, Ms. Noci's direct beneficial ownership of Class A Common Stock is 48,034 shares.
• Ms. Noci continues to hold 21,259 stock options with an exercise price of $14.40 and 142,329 stock options with an exercise price of $27.85.
• The options exercised had vesting schedules: the 2,129 shares option began vesting on August 1, 2023, and the 1,871 shares option began vesting on January 6, 2023, both subject to continued service.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transactions are routine insider activity under a pre-planned Rule 10b5-1 program, which is common for executives managing their equity compensation and personal finances. It does not signal a strong positive or negative outlook on the company's future.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-scheduled activity rather than a reaction to immediate market conditions or new information, which can reduce concerns about opportunistic insider selling.
• The exercise of stock options at lower prices ($14.40 and $27.85) and subsequent sale at significantly higher market prices (around $71) demonstrates a realization of value from previously granted equity compensation.

Negatives

• The sale of 4,000 shares by a Chief Development Officer, even if pre-planned, represents a reduction in direct equity holdings, which some investors might interpret as a lack of increased confidence, though this is common for liquidity or tax purposes.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook. It solely reports past insider transactions.

Industry Context

This filing is a routine disclosure of insider trading activity, common across all publicly traded industries. It does not provide specific insights into broader industry trends or competitive dynamics within the biotechnology or pharmaceutical sector where Nuvalent operates.

Stakeholder Impact

• Shareholders: The transactions represent a routine insider sale for liquidity, which is generally not considered a significant signal for the company's prospects, especially given the Rule 10b5-1 plan. It does not directly impact the company's operations or financial health.

Key Dates

Keywords

Nuvalent, NUVL, Form 4, Insider Trading, Stock Options, Darlene Noci, Chief Development Officer, Rule 10b5-1 Plan, Equity Compensation